LGD-4033 (Ligandrol)
el-gee-dee-four-oh-three-three
Category
Compound type
Phase / Status
Phase 2 clinical trials completed. Not FDA approved for general use.
Standard Dose
Once daily
Half-life
Plasma elimination
Route(s)
Intramuscular, Subcutaneous or Oral
Research Stage
Research phase not specified; exercise appropriate caution.
Overview
LGD-4033 is often discussed as a potent SARM for lean-mass and strength goals. However, it can affect the endocrine system, including possible testosterone suppression, and safety monitoring is important.
Plain-language summary
LGD-4033 is often discussed as a potent SARM for lean-mass and strength goals. However, it can affect the endocrine system, including possible testosterone suppression, and safety monitoring is important.
Administration Routes
- Intramuscular
- Subcutaneous
- Oral
Also known as
Mechanisms
Selective androgen receptor modulator (SARM) — binds androgen receptors with a degree of tissue selectivity intended to target muscle and bone. Endocrine effects may still occur.
Detailed mechanism
Selective androgen receptor modulator (SARM) — binds to androgen receptors with high affinity and selectivity intended for muscle and bone. Endocrine effects may still occur.
Safety
Side effects
- Possible testosterone suppression (requires clinician-informed endocrine monitoring)
- Headache (especially at higher exposures)
- Nausea or GI upset
- Fatigue reported by some users
- Possible lipid changes (e.g., decreased HDL)
Reported benefits
- Lean mass increases reported in research contexts
- Strength and power improvements reported in some users
- Bone mineral density support reported in studies
- Minimal water retention compared with some anabolic approaches
Safety profile
Safety profile has been evaluated in trial contexts, but endocrine and metabolic effects may occur. Monitoring is recommended when considering use.
Clinical trials
Phase 2 clinical trials completed with promising results in studied populations.
Structure
Verified structure
LGD-4033 (Ligandrol)
Exact 2D structure can be rendered from a PubChem-backed canonical SMILES string.
- Chemical Formula
- C14H12F6N2O
- Molecular Weight
- 338.25 g/mol
- CAS Number
- 1165910-22-4
- InChIKey
- OPSIVAKKLQRWKC-VXGBXAGGSA-N
Stack Context
Stacks with
Comparison context
Compared with some other SARMs, LGD-4033 is often discussed as stronger for lean-mass goals, but it may come with a different side-effect and suppression profile.
References
- 1View source
The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men (J Gerontol A Biol Sci Med Sci)
2013
- 2View source
Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit (Mol Interv)
2009
- 3View source
LGD-4033 in Hip Fracture Recovery - Phase 2 Registered Clinical Study (ClinicalTrials.gov NCT01009762)
2013
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.